高播散风险前列腺癌男性接受初始局部根治性治疗或初始雄激素剥夺治疗的生存比较
瑞典1996至2010年基于人群的观察性研究,纳入高播散风险前列腺癌(PSA>50)男性,初始接受根治性治疗(放疗n=630或根治性前列腺切除术n=120)或雄激素剥夺治疗(n=17 602),随访至15年。非匹配队列中雄激素剥夺治疗组前列腺癌死亡为9062/17 602 vs 根治性治疗组86/750,匹配队列中为177/575 vs 71/575,匹配后初始雄激素剥夺治疗与前列腺癌死亡风险接近三倍(HR 2.87,95%CI 2.16-3.82)。作者认为初始根治性治疗可能改善生存。
要点
- 高播散风险(PSA>50)前列腺癌男性中,初始雄激素剥夺治疗组前列腺癌死亡明显高于根治性治疗组。
- 匹配队列中初始雄激素剥夺治疗与前列腺癌死亡风险接近三倍相关(HR 2.87,95%CI 2.16-3.82)。
- 多种敏感性分析提示结果稳健,但非随机研究的普遍局限性仍存在。
核心结论
- 这项大型、全面的基于人群的研究提示,高播散风险前列腺癌男性接受初始根治性治疗可改善生存。
研究设计与样本
- 瑞典1996至2010年基于人群的观察性研究,纳入高播散风险前列腺癌(PSA>50)男性,初始接受根治性治疗(放疗n=630或根治性前列腺切除术n=120)或雄激素剥夺治疗(n=17 602),随访至15年。
- 将两队列按分级、T分期、M分期、Charlson评分、诊断年份、年龄和PSA进行匹配,为575例根治性治疗患者找到雄激素剥夺治疗匹配者,并重复比较效果分析。
主要发现
- 非匹配队列中,雄激素剥夺治疗组前列腺癌死亡为9062/17 602 vs 根治性治疗组86/750。
- 匹配队列中,雄激素剥夺治疗组前列腺癌死亡为177/575 vs 根治性治疗组71/575。
- 匹配队列中,初始雄激素剥夺治疗与前列腺癌死亡风险接近三倍相关(HR 2.87,95%CI 2.16-3.82)。
- 多种敏感性分析提示结果稳健。
临床怎么用
- 原文未据此给出推荐。
局限性
- 非随机研究的普遍局限性仍存在。
- 研究队列可能同时包含系统性和非系统性疾病的男性,因为仅以PSA>50作为唯一入选标准。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: There is increasing low-quality evidence rationalizing the use of radical therapy for men at high risk of disseminated prostate cancer. OBJECTIVE: To investigate, using high-quality epidemiologic data, whether initial radical therapy in men at high risk of disseminated prostate cancer improves survival. DESIGN, SETTING, AND PARTICIPANTS: An observational population-based Swedish study from 1996 to 2010 of men at high risk of disseminated prostate cancer (prostate-specific antigen [PSA] >50) initially treated by radical therapy (radiation therapy [n=630] or radical prostatectomy [n=120]) or androgen deprivation therapy (n=17 602), and followed for up to 15 yr. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: Prostate-cancer and other-cause mortality was estimated for the treatment groups. We also matched the two cohorts for grade, T stage, M stage, Charlson score, year of diagnosis, age, and PSA, and found androgen deprivation therapy patient matches for 575 of the radical therapy patients, and then repeated comparative effectiveness analyses. RESULTS AND LIMITATION: Prostate-cancer mortality was substantially greater in the androgen deprivation therapy group compared with the radically treated one, in unmatched (9062/17 602 vs 86/750) and matched (177/575 vs 71/575) cohorts. Among matched cohorts, initial androgen deprivation therapy was associated with nearly three-fold higher hazard of prostate-cancer death compared with initial radical therapy (2.87; 95% confidence interval 2.16-3.82). Multiple sensitivity analyses suggested that the findings were robust, although the general limitations of nonrandomized studies remain. Further, the study cohort may have included men with both systemic and nonsystemic disease, as a sole eligibility criterion of PSA >50 was used. CONCLUSIONS: This large and comprehensive population-based study suggests that initial radical therapy in men at high risk of disseminated prostate cancer improves survival. PATIENT SUMMARY: This large Swedish study suggests that men with prostate cancer that has spread beyond the prostate benefit from treating the prostate itself with radiation therapy or surgery rather than treating the disease with hormones alone.
引用
- Sooriakumaran P, Nyberg T, Akre O, et al. Survival Among Men at High Risk of Disseminated Prostate Cancer Receiving Initial Locally Directed Radical Treatment or Initial Androgen Deprivation Therapy. Eur Urol. 2017. PMID: 28416350. doi:10.1016/j.eururo.2017.04.002
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。